tbuckley/cabot-search huggingface dataset:
Spatial Architecture of Myeloid and T Cells Orchestrates Immune Evasion and Clinical Outcome in Lung Cancer
Authors: Katey S.S. Enfield, Emma Colliver, Claudia Lee, Alastair Magness, David A. Moore, Monica Sivakumar, Kristiana Grigoriadis, Oriol Pich, Takahiro Karasaki, Philip S. Hobson, Dina Levi, Selvaraju Veeriah, Clare Puttick, Emma L. Nye, Mary Green, Krijn K. Dijkstra, Masako Shimato, Ayse U. Akarca, Teresa Marafioti, Roberto Salgado, Allan Hackshaw, Mariam Jamal-Hanjani, Febe van Maldegem, Nicholas McGranahan, Benjamin Glass, Hanna Pulaski, Eric Walk, James L. Reading, Sergio A. Quezada, Crispin T. Hiley, Julian Downward, Erik Sahai, Charles Swanton, Mihaela Angelova
Journal: Cancer Discovery (2024)

Abstract Understanding the role of the tumor microenvironment (TME) in lung cancer is critical to improving patient outcomes. We identified four histology-independent archetype TMEs in treatment-naïve early-stage lung cancer using imaging mass cytometry in the TRACERx study (n = 81 patients/198 samples/2.3 million cells). In immune-hot adenocarcinomas, spatial niches of T cells and macrophages increased with clonal neoantigen burden, whereas such an increase was observed for niches of plasma and B cells in immune-excluded squamous cell carcinomas (LUSC). Immune-low TMEs were associated with fibroblast barriers to immune infiltration. The fourth archetype, characterized by sparse lymphocytes and high tumor-associated neutrophil (TAN) infiltration, had tumor cells spatially separated from vasculature and exhibited low spatial intratumor heterogeneity. TAN-high LUSC had frequent PIK3CA mutations. TAN-high tumors harbored recently expanded and metastasis-seeding subclones and had a shorter disease-free survival independent of stage. These findings delineate genomic, immune, and physical barriers to immune surveillance and implicate neutrophil-rich TMEs in metastasis. Significance: This study provides novel insights into the spatial organization of the lung cancer TME in the context of tumor immunogenicity, tumor heterogeneity, and cancer evolution. Pairing the tumor evolutionary history with the spatially resolved TME suggests mechanistic hypotheses for tumor progression and metastasis with implications for patient outcome and treatment. This article is featured in Selected Articles from This Issue, p. 897
Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial
Authors: Adrian F. Hernandez, Jacob A. Udell, W. Schuyler Jones, Stefan D. Anker, Mark C. Petrie, Josephine Harrington, Michaela Mattheus, Svenja Seide, Isabella Zwiener, Offer Amir, M. Cecilia Bahit, Johann Bauersachs, Antoni Bayes-Genis, Yundai Chen, Vijay K. Chopra, Gemma A. Figtree, Junbo Ge, Shaun G. Goodman, Nina Gotcheva, Shinya Goto, Tomasz Gasior, Waheed Jamal, James L. Januzzi, Myung Ho Jeong, Yuri Lopatin, Renato D. Lopes, Béla Merkely, Puja B. Parikh, Alexander Parkhomenko, Piotr Ponikowski, Xavier Rossello, Morten Schou, Dragan Simic, Philippe Gabriel Steg, Joanna Szachniewicz, Peter van der Meer, Dragos Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Javed Butler
Journal: Circulation (2024)

BACKGROUND: Empagliflozin reduces the risk of heart failure (HF) events in patients with type 2 diabetes at high cardiovascular risk, chronic kidney disease, or prevalent HF irrespective of ejection fraction. Whereas the EMPACT-MI trial (Effect of Empagliflozin on Hospitalization for Heart Failure and Mortality in Patients With Acute Myocardial Infarction) showed that empagliflozin does not reduce the risk of the composite of hospitalization for HF and all-cause death, the effect of empagliflozin on first and recurrent HF events after myocardial infarction is unknown. METHODS: EMPACT-MI was a double-blind, randomized, placebo-controlled, event-driven trial that randomized 6522 patients hospitalized for acute myocardial infarction at risk for HF on the basis of newly developed left ventricular ejection fraction of &lt;45% or signs or symptoms of congestion to receive empagliflozin 10 mg daily or placebo within 14 days of admission. In prespecified secondary analyses, treatment groups were analyzed for HF outcomes. RESULTS: Over a median follow-up of 17.9 months, the risk for first HF hospitalization and total HF hospitalizations was significantly lower in the empagliflozin compared with the placebo group (118 [3.6%] versus 153 [4.7%] patients with events; hazard ratio, 0.77 [95% CI, 0.60, 0.98]; P =0.031, for first HF hospitalization; 148 versus 207 events; rate ratio, 0.67 [95% CI, 0.51, 0.89]; P =0.006, for total HF hospitalizations). Subgroup analysis showed consistency of empagliflozin benefit across clinically relevant patient subgroups for first and total HF hospitalizations. The need for new use of diuretics, renin-angiotensin modulators, or mineralocorticoid receptor antagonists after discharge was less in patients randomized to empagliflozin versus placebo (all P &lt;0.05). CONCLUSIONS: Empagliflozin reduced the risk of HF in patients with left ventricular dysfunction or congestion after acute myocardial infarction. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04509674.
A deep learning approach to direct immunofluorescence pattern recognition in autoimmune bullous diseases
Authors: Niccolò Capurro, Vito Paolo Pastore, Larbi Touijer, Francesca Odone, Emanuele Cozzani, Giulia Gasparini, Aurora Parodi
Journal: British Journal of Dermatology (2024)

Artificial intelligence (AI) is reshaping healthcare, using machine and deep learning (DL) to enhance disease management. Dermatology has seen improved diagnostics, particularly in skin cancer detection, through the integration of AI. However, the potential of AI in automating immunofluorescence imaging for autoimmune bullous skin diseases (AIBDs) remains untapped. While direct immunofluorescence (DIF) supports diagnosis, its manual interpretation can hinder efficiency. The use of DL to classify DIF patterns automatically, including the intercellular (ICP) and linear pattern (LP), holds promise for improving the diagnosis of AIBDs.
Effect of Reconstituted Human Apolipoprotein A-I on Recurrent Ischemic Events in Survivors of Acute MI
Authors: Thomas J. Povsic, Serge Korjian, M. Cecilia Bahit, Gerald Chi, Danielle Duffy, John H. Alexander, Dragos Vinereanu, Pierluigi Tricoci, Sojaita Jenny Mears, Lawrence I. Deckelbaum, Marc Bonaca, Paul M. Ridker, Shaun G. Goodman, Jan H. Cornel, Basil S. Lewis, Alexander Parkhomenko, Renato D. Lopes, Philip Aylward, A. Michael Lincoff, Mark Heise, Frank Sacks, Jose C. Nicolau, Bela Merkely, Jaroslaw Trebacz, Peter Libby, Stephen J. Nicholls, Stuart Pocock, Deepak L. Bhatt, John Kastelein, Christoph Bode, Kenneth W. Mahaffey, P. Gabriel Steg, Michal Tendera, Kevin R. Bainey, Robert A. Harrington, Roxana Mehran, Daniel Duerschmied, Bronwyn A. Kingwell, C. Michael Gibson
Journal: Journal of the American College of Cardiology (2024)

The AEGIS-II trial hypothesized that CSL112, an intravenous formulation of human apoA-I, would lower the risk of plaque disruption, decreasing the risk of recurrent events such as myocardial infarction (MI) among high-risk patients with MI. This exploratory analysis evaluates the effect of CSL112 therapy on the incidence of CV death and recurrent MI. The AEGIS-II trial was an international, multicenter, randomized, double-blind, placebo-controlled trial that randomized 18,219 high-risk acute MI patients to 4 weekly infusions of apoA-I (6g CSL112) or placebo. The incidence of the composite of cardiovascular death and type 1 MI was 11-16% lower in the CSL112 group over the study period (HR of 0.84 [95% CI 0.7-1.0; p=0.056] day 90, HR 0.86, [95% CI 0.74-0.99; p=0.048] day 180, and HR 0.89, [95% CI 0.79-1.01 p=0.07; p=0.07] day 365). Similarly, the incidence of CV death or any MI was numerically lower in CSL112 treated patients throughout the follow-up period (HR 0.92 [95% CI 0.8-1.05], 0.89 [95% CI 0.79-0.996], 0.91 [0.82-1.01]. The effect of CSL112 treatment on MI was predominantly observed for type 1 MI and type 4b (MI due to stent thrombosis). While CSL112 did not significantly reduce the occurrence of the primary study endpoints, patients treated with CSL112 infusions had numerically lower rates of CV death and MI, type-1 MI, and stent thrombosis-related MI compared to placebo. These findings could suggest a role of apoA-I in reducing subsequent plaque disruption events via enhanced cholesterol efflux. Further prospective data would be needed to confirm these observations.
A Molecular Voyage: Multiomics Insights into Circulating Tumor Cells
Authors: Yu Wei Zhang, Ana Gvozdenovic, Nicola Aceto
Journal: Cancer Discovery (2024)

Abstract Circulating tumor cells (CTCs) play a pivotal role in metastasis, the leading cause of cancer-associated death. Recent improvements of CTC isolation tools, coupled with a steady development of multiomics technologies at single-cell resolution, have enabled an extensive exploration of CTC biology, unlocking insights into their molecular profiles. A detailed molecular portrait requires CTC interrogation across various levels encompassing genomic, epigenetic, transcriptomic, proteomic and metabolic features. Here, we review how state-of-the-art multiomics applied to CTCs are shedding light on how cancer spreads. Further, we highlight the potential implications of CTC profiling for clinical applications aimed at enhancing cancer diagnosis and treatment. Significance: Exploring the complexity of cancer progression through cutting-edge multiomics studies holds the promise of uncovering novel aspects of cancer biology and identifying therapeutic vulnerabilities to suppress metastasis.
Left Ventricular Function, Congestion, and Effect of Empagliflozin on Heart Failure Risk After Myocardial Infarction
Authors: Jacob A. Udell, Mark C. Petrie, W. Schuyler Jones, Stefan D. Anker, Josephine Harrington, Michaela Mattheus, Svenja Seide, Offer Amir, M. Cecilia Bahit, Johann Bauersachs, Antoni Bayes-Genis, Yundai Chen, Vijay K. Chopra, Gemma Figtree, Junbo Ge, Shaun G. Goodman, Nina Gotcheva, Shinya Goto, Tomasz Gasior, Waheed Jamal, James L. Januzzi, Myung Ho Jeong, Yuri Lopatin, Renato D. Lopes, Béla Merkely, Monica Martinez-Traba, Puja B. Parikh, Alexander Parkhomenko, Piotr Ponikowski, Xavier Rossello, Morten Schou, Dragan Simic, Philippe Gabriel Steg, Joanna Szachniewicz, Peter van der Meer, Dragos Vinereanu, Shelley Zieroth, Martina Brueckmann, Mikhail Sumin, Deepak L. Bhatt, Adrian F. Hernandez, Javed Butler
Journal: Journal of the American College of Cardiology (2024)

Empagliflozin reduces the risk of heart failure (HF) hospitalizations but not all-cause mortality when started within 14 days of acute myocardial infarction (AMI). To evaluate the association between left ventricular ejection fraction (LVEF), congestion, or both on outcomes and the impact of empagliflozin in reducing HF risk post-MI. In the EMPACT-MI trial, patients were randomized within 14 days of an AMI complicated by either newly reduced LVEF<45%, congestion, or both to empagliflozin 10 mg daily or placebo and followed for a median of 17.9 months. Among 6522 patients, the mean baseline LVEF was 41%+9%; 2648 patients (40.6%) presented with LVEF<45% alone, 1483 (22.7%) presented with congestion alone, and 2181 (33.4%) presented with both. Among patients in the placebo arm, multivariable adjusted risk for each 10-point reduction in LVEF included all-cause death or HF hospitalization (hazard ratio [HR] 1.49; 95%CI, 1.31-1.69; P<0.0001), first HF hospitalization (HR, 1.64; 95%CI, 1.37-1.96; P<0.0001), and total HF hospitalizations (rate ratio [RR], 1.89; 95%CI, 1.51-2.36; P<0.0001). Presence of congestion was also associated with a significantly higher risk for each of these outcomes (HR 1.52, 1.94, and RR 2.03, respectively). Empagliflozin reduced the risk for first (HR 0.77, 95%CI 0.60-0.98) and total (RR 0.67, 95%CI 0.50-0.89) HF hospitalization, irrespective of LVEF or congestion or both. The safety profile of empagliflozin was consistent across baseline LVEF and irrespective of congestion status. In patients with AMI, severity of LV dysfunction and the presence of congestion was associated with worse outcomes. Empagliflozin reduced first and total HF hospitalizations across the range of LVEF with and without congestion.
Effects of Sacubitril/Valsartan Across the Spectrum of Renal Impairment in Patients With Heart Failure
Authors: Safia Chatur, Brendon L. Neuen, Brian L. Claggett, Iris E. Beldhuis, Finnian R. Mc Causland, Akshay S. Desai, Jean L. Rouleau, Michael R. Zile, Martin P. Lefkowitz, Milton Packer, John J.V. McMurray, Scott D. Solomon, Muthiah Vaduganathan
Journal: Journal of the American College of Cardiology (2024)
Hepatocellular carcinoma surveillance among people living with hepatitis B in Senegal (SEN-B): insights from a prospective cohort study
Authors: Adrià Ramírez Mena, Mbaye Thiam, Daye Ka, Ibrahima Niang, Judicaël Tine, Louise Fortes, Kiné Ndiaye, Ousseynou Ndiaye, Maguette Fall, Assietou Gaye, Ndeye Fatou Ngom, Fatou Fall, Annalisa Berzigotti, Gregory Dale Kirk, Antoine Jaquet, Moussa Seydi, Gilles Wandeler
Journal: The Lancet. Gastroenterology & hepatology (2024)
Intranasal delivery of low-dose anti-CD124 antibody enhances treatment of chronic rhinosinusitis with nasal polyps
Authors: Jiamin Wu, Natalie Jones, Po-Han Chao, Vanessa Chan, Lukas Hohenwarter, Angeline Wu, Marta Bergamo, Cristina Rodríguez-Rodríguez, Katayoun Saatchi, Alex Liang, Urs O. Häfeli, Zheng Tan, Sarah Hedtrich, Lucas J. Andrew, Shyh-Dar Li
Journal: Biomaterials (2024)
Mandibular Advancement vs CPAP for Blood Pressure Reduction in Patients With Obstructive Sleep Apnea
Authors: Yi-Hui Ou, Juliana Tereza Colpani, Crystal S. Cheong, Weiqiang Loke, As tar Thant, E’ Ching Shih, Frank Lee, Siew-Pang Chan, Ching-Hui Sia, Chieh-Yang Koo, Serene Wong, Aiping Chua, Chin-Meng Khoo, William Kong, Calvin W. Chin, Pipin Kojodjojo, Philip E. Wong, Mark Y. Chan, A. Mark Richards, Peter A. Cistulli, Chi-Hang Lee
Journal: Journal of the American College of Cardiology (2024)

Hypertension guidelines recommend diagnosis and treatment of obstructive sleep apnea (OSA) in patients with hypertension. The mandibular advancement device (MAD) is an oral appliance therapy for patients who decline or cannot tolerate CPAP. We compared the relative effectiveness of MAD versus CPAP in reducing 24-hour ambulatory BP. In an investigator-initiated, randomized, non-inferiority trial (pre-specified margin 1.5 mmHg), 321 participants, aged over 40, with hypertension and increased cardiovascular risk were recruited at 3 public hospitals for polysomnography. Of these, 220 participants with moderate-to-severe OSA (apnea–hypopnea index (AHI) ≥15 events/hour) were randomized to either MAD or CPAP (1:1). The primary outcome was the difference between the 24-hour mean arterial BP at baseline and 6 months. Compared to baseline, the 24-hour mean arterial BP decreased by 2.5 mmHg (P = 0.003) at 6 months in the MAD group, whereas no change was observed in the CPAP group (P = 0.374). The between-group difference was -1.6 mmHg (95% confidence interval: -3.51 to 0.24, non-inferiority P < 0.001). The MAD group demonstrated a larger between-group reduction in all secondary ambulatory BP parameters compared to the CPAP group, with the most pronounced effects observed in the asleep BP parameters. Both the MAD and CPAP improved daytime sleepiness, with the between-group difference similar (P = 0.384). There were no between-group differences in cardiovascular biomarkers. MAD is non-inferior to CPAP for reducing 24-hour mean arterial BP in participants with hypertension and increased cardiovascular risk.
Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy
Authors: Yan-Ruide Li, Yang Zhou, Jiaji Yu, Yichen Zhu, Derek Lee, Enbo Zhu, Zhe Li, Yu Jeong Kim, Kuangyi Zhou, Ying Fang, Zibai Lyu, Yuning Chen, Yanxin Tian, Jie Huang, Xinjian Cen, Tiffany Husman, Jae Min Cho, Tzung Hsiai, Jin J Zhou, Pin Wang, Benjamin R Puliafito, Sarah M Larson, Lili Yang
Journal: Molecular Therapy (2024)

The clinical potential of current FDA-approved chimeric antigen receptor (CAR)-engineered T (CAR-T) cell therapy is encumbered by its autologous nature, which presents notable challenges related to manufacturing complexities, heightened costs, and limitations in patient selection. Therefore, there is a growing demand for off-the-shelf universal cell therapies. In this study, we have generated universal CAR-engineered NKT (
Extramammary Paget disease. Part II. Evidence-based approach to management
Authors: Rohan R. Shah, Kalee Shah, Britney N. Wilson, Mario M. Leitao, Jan Smogorzewski, Kevin A. Nguyen, Christopher Crane, Samuel A. Funt, Sharif Hosein, Mirabel Dafinone, Anthony Rossi
Journal: Journal of the American Academy of Dermatology (2024)
Randomized Trial of Remote Assessment of Patients After an Acute Coronary Syndrome
Authors: Nasser S. Alshahrani, Adam Hartley, James Howard, Reza Hajhosseiny, Saud Khawaja, Henry Seligman, Tamim Akbari, Badr A. Alharbi, Paul Bassett, Rasha Al-Lamee, Darrel Francis, Amit Kaura, Mihir A. Kelshiker, Nicholas S. Peters, Ramzi Khamis
Journal: Journal of the American College of Cardiology (2024)
Nanomodulators targeting endothelial WNT and pericytes to reversibly open the blood–tumor barrier for boosted brain tumor therapy
Authors: Rui Mu, Hang Sun, Yuteng Zeng, Yang Tong, Puxian Tang, Mei Zhao, Ziyan Lv, Ju Yu, Yanming Chen, Qing Lan, Xuechu Zhen, Liang Han
Journal: Journal of Controlled Release (2024)
Next-Gen GWAS: full 2D epistatic interaction maps retrieve part of missing heritability and improve phenotypic prediction
Authors: Clément Carré, Jean Baptiste Carluer, Christian Chaux, Chad Estoup-Streiff, Nicolas Roche, Eric Hosy, André Mas, Gabriel Krouk
Journal: Genome biology (2024)

Abstract The problem of missing heritability requires the consideration of genetic interactions among different loci, called epistasis. Current GWAS statistical models require years to assess the entire combinatorial epistatic space for a single phenotype. We propose Next-Gen GWAS (NGG) that evaluates over 60 billion single nucleotide polymorphism combinatorial first-order interactions within hours. We apply NGG to Arabidopsis thaliana providing two-dimensional epistatic maps at gene resolution. We demonstrate on several phenotypes that a large proportion of the missing heritability can be retrieved, that it indeed lies in epistatic interactions, and that it can be used to improve phenotype prediction.
Cutaneous T-cell lymphoma care across Europe: insights from the HORIZON programme
Authors: Gabriele Roccuzzo, Joana Calvão, Gabor Dobos, Erika Morsia, Pablo Mozas, Elizabeth Peterknecht, Anne M R Schrader, Francesca Zottarelli, Martine Bagot, Rudolf Stadler, Maarten Vermeer, Pietro Quaglino, Julia Scarisbrick
Journal: British Journal of Dermatology (2024)

In this perspective we provide BJD readers with an overview of the HORIZON programme. It illuminates the diverse perspectives of specialists across five prominent European centres of excellence in the field of CTCL.
Treatment response as surrogate to predict risk for disease progression in pediatric medulloblastoma with persistent magnetic resonance imaging lesions after first-line treatment
Authors: Denise Obrecht-Sturm, Lena Schömig, Martin Mynarek, Brigitte Bison, Rudolf Schwarz, Torsten Pietsch, Stefan M Pfister, Martin Sill, Dominik Sturm, Felix Sahm, Rolf-Dieter Kortmann, Nicolas U Gerber, André O von Bueren, Gudrun Fleischhack, Ulrich Schüller, Gunther Nussbaumer, Martin Benesch, Stefan Rutkowski
Journal: Neuro-Oncology (2024)

Abstract Background This study aims at clarifying the impact of persistent residual lesions following first-line treatment for pediatric medulloblastoma. Methods Data on 84 pediatric patients with medulloblastoma and persistent residual lesions on centrally reviewed magnetic resonance imaging (MRI) at the end of first-line therapy were analyzed. Results Twenty patients (23.8%) had residual lesions in the tumor bed (R+/M0), 51 (60.7%) had distant lesions (R0/M+) and 13 (15.5%) had both (R+/M+). Overall response to first-line therapy was minor or partial (≥ 25% reduction, minor response [MR]/PR) for 64 (76.2%) and stable disease (SD) for 20 patients (23.8%). Five-year post-primary-treatment progression-free (pptPFS) and overall survival (pptOS) were superior after MR/PR (pptPFS: 62.5 ± 7.0%[MR/PR] vs. 35.9 ± 12.8%[SD], P = .03; pptOS: 79.7 ± 5.9[MR/PR] vs. 55.5 ± 13.9[SD], P = .04). Furthermore, R+/M + was associated with a higher risk for progression (5-year pptPFS: 22.9 ± 17.9%[R+, M+] vs. 72.4 ± 12.0%[R+, M0]; P = .03). Watch-and-wait was pursued in 58 patients, while n = 26 received additional treatments (chemotherapy only, n = 19; surgery only, n = 2; combined, n = 3; valproic acid, n = 2), and their outcomes were not superior to watch-and-wait (5-year pptPFS: 58.5 ± 7.7% vs. 51.6 ± 10.7% P = .71; 5-year pptOS: 76.3 ± 6.9% vs. 69.8 ± 9.7%, P = .74). For the whole cohort, 5-year pptPFS by molecular subgroup (58 cases) were WNT: 100%, SHH: 50.0 ± 35.4%, group-4, 52.5 ± 10.5, group-3 54.2 ± 13.8%; (P = .08). Conclusions Overall response and extent of lesions can function as surrogate parameters to predict outcomes in pediatric MB patients with persistent lesions after first-line therapy. Especially in the case of solitary persistent medulloblastoma MRI lesions, additional therapy was not beneficial. Therefore, treatment response, extent/kind of residual lesions and further diagnostic information need consideration for indication of additional treatments for persisting lesions.
fastDFE: Fast and Flexible Inference of the Distribution of Fitness Effects
Authors: Janek Sendrowski, Thomas Bataillon
Journal: Molecular Biology and Evolution (2024)

Abstract Estimating the distribution of fitness effects (DFE) of new mutations is of fundamental importance in evolutionary biology, ecology, and conservation. However, existing methods for DFE estimation suffer from limitations, such as slow computation speed and limited scalability. To address these issues, we introduce fastDFE, a Python-based software package, offering fast, and flexible DFE inference from site-frequency spectrum (SFS) data. Apart from providing efficient joint inference of multiple DFEs that share parameters, it offers the feature of introducing genomic covariates that influence the DFEs and testing their significance. To further simplify usage, fastDFE is equipped with comprehensive VCF-to-SFS parsing utilities. These include options for site filtering and stratification, as well as site-degeneracy annotation and probabilistic ancestral-allele inference. fastDFE thereby covers the entire workflow of DFE inference from the moment of acquiring a raw VCF file. Despite its Python foundation, fastDFE incorporates a full R interface, including native R visualization capabilities. The package is comprehensively tested and documented at fastdfe.readthedocs.io.
Towards more tolerable subcutaneous administration: Review of contributing factors for improving combination product design
Authors: Neil Mathias, Sylvain Huille, Marie Picci, Robert P. Mahoney, Ronald J. Pettis, Brian Case, Bernhard Helk, David Kang, Ronak Shah, Junchi Ma, Deep Bhattacharya, Yogita Krishnamachari, Dany Doucet, Nathalie Maksimovikj, Sahab Babaee, Patrick Garidel, Reza Esfandiary, Rajesh Gandhi
Journal: Advanced Drug Delivery Reviews (2024)
Telephone-Based Guideline-Directed Medical Therapy Optimization in Navajo Nation
Authors: Lauren A. Eberly, Ada Tennison, Daniel Mays, Chih-Yuan Hsu, Chih-Ting Yang, Ernest Benally, Harriett Beyuka, Benjamin Feliciano, C. Jane Norman, Maria Ynes Brueckner, Clybert Bowannie, Daniel R. Schwartz, Erica Lindsey, Stephen Friedman, Elizabeth Ketner, Pamela Detsoi-Smiley, Yu Shyr, Sonya Shin, Maricruz Merino
Journal: JAMA Internal Medicine (2024)

Underutilization of guideline-directed medical therapy for heart failure with reduced ejection fraction is a major cause of poor outcomes. For many American Indian patients receiving care through the Indian Health Service, access to care, especially cardiology care, is limited, contributing to poor uptake of recommended therapy.